The anti-BCMA CAR T-cell therapy bb21217 demonstrated an objective response rate (ORR) of 83.3%, with a very good partial response (VGPR) or better rate of 75% in patients with heavily pretreated relapsed/refractory multiple myeloma, according to initial results from a phase I study presented at the 2018 ASH Annual Meeting.1
In the preliminary results from the phase I study, responses deepened over time, with complete remissions (CR) achieved out to 10 months following infusion. The CR or stringent CR rate was 25%, with a minimal residual disease (MRD)-negativity rate of 100% in this group. The time to first response and best response were both 1 month.
“bb21217 demonstrated promising early clinical activity in heavily pretreated patients with relapsed/refractory multiple myeloma at first dose level tested,” said Nina Shah, MD, from the University of California, San Francisco. “Longer follow-up in a larger patient population will clarify the depth and durability of bb21217 tumor responses and dose response.”
Read more at: https://www.oncnursingnews.com/web-exclusives/next-generation-bcma-car-t-cell-therapy-effective-for-heavily-pretreated-myeloma